

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/060,561		01/30/2002	James E. Dvorsky	VI/99-020	7657	
21140	7590	10/11/2005		EXAMINER		
GREGOR	Y L BRA	DLEY	SMITH, RUTH S			
MEDRAD	INC					
ONE MED	RAD DRI	VE	ART UNIT	PAPER NUMBER		
INDIANO	LA, PA	15051	3737			

DATE MAILED: 10/11/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

			·	92Ch				
	App	olication No.	Applicant(s)					
Office Action Summary		060,561	DVORSKY ET AL.					
		miner	Art Unit					
		h S. Smith	3737					
The MAILING DATE of this of Period for Reply	communication appears	on the cover sheet with the o	correspondence ad	ddress				
A SHORTENED STATUTORY PE WHICHEVER IS LONGER, FROM - Extensions of time may be available under the after SIX (6) MONTHS from the mailing date of - If NO period for reply is specified above, the n - Failure to reply within the set or extended period for reply received by the Office later than three earned patent term adjustment. See 37 CFR	THE MAILING DATE ( provisions of 37 CFR 1.136(a). If this communication. Inaximum statutory period will applied for reply will, by statute, cause months after the mailing date of	OF THIS COMMUNICATION  In no event, however, may a reply be time  It and will expire SIX (6) MONTHS from  It the application to become ABANDONE	N. mely filed the mailing date of this of ED (35 U.S.C. § 133).					
Status								
1)⊠ Responsive to communication(s) filed on <u>05 April 2005</u> .								
2a) This action is FINAL.	on is non-final.							
,	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims			•					
4) ⊠ Claim(s) <u>7-13,16-24 and 27-4</u> 4a) Of the above claim(s) 5) ⊠ Claim(s) <u>7,8,11-13,16-21,27</u> 6) ⊠ Claim(s) <u>22 and 28-30</u> is/are 7) ⊠ Claim(s) <u>9,10,23,24,31,32 and 28-30</u>	<ul> <li>✓ Claim(s) 7-13,16-24 and 27-41 is/are pending in the application.</li> <li>4a) Of the above claim(s) is/are withdrawn from consideration.</li> <li>✓ Claim(s) 7,8,11-13,16-21,27,33-38,40 and 41 is/are allowed.</li> <li>✓ Claim(s) 22 and 28-30 is/are rejected.</li> <li>✓ Claim(s) 9,10,23,24,31,32 and 39 is/are objected to.</li> </ul>							
Application Papers								
9) The specification is objected to by the Examiner.								
	0)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority under 35 U.S.C. § 119								
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>								
Attachment(s)  1)  Notice of References Cited (PTO-892)		4) 🔲 Interview Summar	y (PTO-413)					
2) Notice of Draftsperson's Patent Drawing 3) Information Disclosure Statement(s) (PT Paper No(s)/Mail Date		Paper No(s)/Mail I  5) Notice of Informal  6) Other:	Date	<sup>-</sup> O-152)				

# Claim Objections

Claims 9-10,23-24,31,32,39 are objected to because of the following informalities: In claim 9, it is unclear as to whether the alarm is in addition to the indicator set forth in claim 7 or whether the alarm is a type of indicator. Claims 22,23 are incomplete in that the claims fail to positively set forth a step of detecting extravasation as set forth in the preamble. In claim 39, lines 13-14 include functional language unsupported by structure to produce such a function. Appropriate correction is required.

# Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 22,28-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Unger et al ('438) in view of Atkins. Unger et al discloses an MR imaging device and a means for detecting a signal that is sensitive to the amount of contrast agent in a body portion. Unger et al disclose mixing an additive with a contrast agent and injecting the mixture into a patient. The additive affects the measured signal. Atkins discloses a

Art Unit: 3737

device that detects the presence of extravasation of an injected contrast medium. Atkins discloses measuring a baseline signal and comparing a measured signal after the injection to the baseline to determine if extravasation has occurred. Extravasation is well known to be harmful to the patient. Therefore, it would have been obvious to one skilled in the art to have modified Unger et al such that the detected amounts of contrast agent can be used to monitor the presence of extravasation in order to reduce the effects of such contrast agent leakage on the patient.

# Allowable Subject Matter

Claims 7-8,11-13,16-21,27,33-38,40-41 are allowable over the prior art of record.

# Response to Arguments

Applicant's arguments filed 4/5/05 have been fully considered but they are not persuasive. It appears that the additive used by Unger et al would affect the signal measured using the device of Atkins et al.

#### Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 3737

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ruth S. Smith whose telephone number is 571-272-4745. The examiner can normally be reached on M-F 7:30 AM-4:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler can be reached on 571-272-4956. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Ruth S. Smith Primary Examiner Art Unit 3737